RxDoctor Payments Data

Muhammed Saif, MD

Addiction Medicine · Albany, NYNPI 1396276697

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Johnson & Johnson accounts for 95.1% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $799 and has fallen 55.1% since, to $359 in 2025.

$2,868in general payments, 2019–2025

Across 106 payments — averaging $27.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • Kyowa Kirin, Inc.$140

What the payments were for

  • Food & beverage$2,868100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson105$2,728
Kyowa Kirin, Inc.1$140

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,868 in reported general payments places this provider in the 80th percentile of 125 addiction medicine providers in New York.

See all addiction medicine providers in New York

Medicare billing

Part B allowed, 2024
$29,368
Medicare patients
82
Services billed
362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Divalproex Sodium ErDivalproex Sodium13$587
Quetiapine Fumarate30$580
Gabapentin20$458
Olanzapine19$324
Mirtazapine36$271
Bupropion XlBupropion Hcl12$260
Clonazepam39$245
Divalproex Sodium12$240
Fluoxetine Hcl17$198
Trazodone Hcl27$180
Risperidone12$169
Benztropine Mesylate13$142
Lamotrigine15$124
Venlafaxine Hcl ErVenlafaxine Hcl11$114
Sertraline Hcl23$100

Paid to pharmacies, not to this prescriber.

Other addiction medicine in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →